Krsnaa Diagnostics quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	236	193	+22.1%
EBITDA	58.0	51.4	+12.8%
EBITDA margin	24.6%	26.6%	−2.0 pts
Profit before tax	22.4	27.4	−18.2%
Net profit	16.6	20.5	−19.3%
EPS	₹5.10	₹6.35	−19.7%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	236	193	181	206	193	186	175	186	170	166	158	155	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	7.2	31.5	3.8	4.2	4.0	4.4	9.2	4.6	7.3	4.3	4.1	4.2
	243	224	185	210	197	190	184	191	178	171	162	160
	50.2	44.4	39.1	48.1	47.4	41.5	39.9	44.9	42.9	43.0	34.4	35.9
	36.1	33.3	36.2	35.4	35.6	32.8	35.9	35.1	33.1	32.5	29.7	26.4
	14.8	12.1	7.8	8.2	6.3	6.8	6.1	6.4	5.3	7.3	4.1	3.1
	28.0	22.6	22.7	23.6	21.6	22.0	22.7	22.2	21.5	18.1	21.2	19.5
	91.3	60.0	59.5	63.3	58.6	58.8	53.7	57.0	51.6	47.1	56.9	61.3
	220	172	165	179	170	162	158	166	154	148	146	146
	58.0	54.9	46.4	59.2	51.4	53.0	45.1	49.4	42.7	43.7	37.4	31.8
	30.0	32.3	23.8	35.6	29.8	31.0	22.4	27.2	21.2	25.6	16.2	12.3
Profit
	22.4	51.7	19.8	31.6	27.4	28.6	25.5	25.4	23.2	22.6	16.1	13.4
	22.4	51.7	19.8	31.6	27.4	28.6	25.5	25.4	23.2	22.6	16.1	13.4
	5.8	8.5	3.6	6.6	5.8	8.9	3.8	5.1	4.0	3.2	2.7	1.7
	0.1	1.5	0.9	1.1	1.1	−1.0	2.3	0.7	1.2	0.7	0.4	1.2
	5.9	10.0	4.4	7.6	6.9	7.9	6.1	5.8	5.3	3.9	3.1	2.9
	0.0	−0.0	−0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
	16.6	41.7	15.2	23.9	20.5	20.7	19.4	19.6	17.9	18.7	13.0	10.5
	16.5	41.7	15.3	23.9	20.5	20.7	19.4	19.6	17.9	18.7	13.0	10.5
	0.1	0.1	−0.1	0.1	0.1	0.7	−0.1	−0.1	−0.1	−0.7	0.3	0.2
	16.6	41.8	15.1	24.0	20.7	21.4	19.3	19.5	17.9	18.0	13.2	10.6
	16.6	41.7	15.2	23.9	20.5	20.7	19.4	—	17.9	18.7	13.0	10.5
Per share
	₹5.10	₹12.86	₹4.72	₹7.38	₹6.35	₹6.40	₹6.01	₹6.07	₹5.55	₹5.80	₹4.09	₹3.35
	₹5.04	₹12.70	₹4.66	₹7.25	₹6.25	₹6.28	₹5.88	₹5.92	₹5.46	₹5.70	₹3.97	₹3.23
Other comprehensive income — detail
	0.1	0.1	−0.1	0.1	0.1	0.7	—	—	—	—	—	—
	0.1	0.1	−0.1	0.1	0.2	0.9	−0.1	−0.1	−0.1	−0.9	0.4	0.2
	0.0	0.0	−0.0	0.0	0.0	0.2	—	—	—	—	—	—
	—	—	—	—	—	—	−0.0	−0.0	−0.0	−0.2	0.1	0.1
	16.6	41.8	15.2	24.0	20.7	21.4	19.3	—	17.9	18.0	13.2	10.6
Per share — as-filed variants
	₹5.10	₹12.86	₹4.72	₹7.38	₹6.35	₹6.40	₹6.01	₹6.07	₹5.55	₹5.80	₹4.09	₹3.35
	₹5.04	₹12.70	₹4.66	₹7.25	₹6.25	₹6.28	₹5.88	₹5.92	₹5.46	₹5.70	₹3.97	₹3.23
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	185	148	142	158	146	145	135	141	127	123	124	120
	78.7%	77.0%	78.4%	76.6%	75.4%	77.7%	77.1%	75.9%	74.8%	74.1%	78.3%	76.9%
Adjusted (ex-exceptional items) — derived
	22.4	51.7	19.8	31.6	27.4	28.6	25.5	25.4	23.2	22.6	16.1	13.4
	16.6	41.7	15.2	23.9	20.5	20.7	19.4	19.6	17.9	18.7	13.0	10.5
	₹5.10	₹12.86	₹4.72	₹7.38	₹6.35	₹6.40	₹6.01	₹6.07	₹5.55	₹5.80	₹4.09	₹3.35

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

KRSNAA₹497.95

Krsnaa Diagnostics Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSURAKSHA HEALTHX NEPHROPLUS 3BBLACKBIOMcap ₹1,615 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	155.4	158.3	166.3	170.2	186.3	174.5	186.1	193.0	206.0	181.2	192.6	235.5
Other Income	4.2	4.1	4.3	7.3	4.6	9.2	4.4	4.0	4.2	3.8	31.5	7.2
Total Income	159.6	162.4	170.6	177.5	190.9	183.7	190.5	196.9	210.2	185.0	224.1	242.8
Expenses
+ Cost of Materials Consumed	35.9	34.4	43.0	42.9	44.9	39.9	41.5	47.4	48.1	39.1	44.4	50.2
+ Employee Benefit Expense	26.4	29.7	32.5	33.1	35.1	35.9	32.8	35.6	35.4	36.2	33.3	36.1
+ Finance Costs	3.1	4.1	7.3	5.3	6.4	6.1	6.8	6.3	8.2	7.8	12.1	14.8
+ Depreciation & Amortisation	19.5	21.2	18.1	21.5	22.2	22.7	22.0	21.6	23.6	22.7	22.6	28.0
+ Other Expenses	61.3	56.9	47.1	51.6	57.0	53.7	58.8	58.6	63.3	59.5	60.0	91.3
Total Expenses	146.2	146.3	148.0	154.3	165.5	158.3	161.9	169.5	178.6	165.2	172.4	220.3
EBITDA	31.8	37.4	43.7	42.7	49.4	45.1	53.0	51.4	59.2	46.4	54.9	58.0
EBIT	12.3	16.2	25.6	21.2	27.2	22.4	31.0	29.8	35.6	23.8	32.3	30.0
Profit
PBT before Exceptional Items	13.4	16.1	22.6	23.2	25.4	25.5	28.6	27.4	31.6	19.8	51.7	22.4
Pretax Income	13.4	16.1	22.6	23.2	25.4	25.5	28.6	27.4	31.6	19.8	51.7	22.4
+ Current Tax	1.7	2.7	3.2	4.0	5.1	3.8	8.9	5.8	6.6	3.6	8.5	5.8
+ Deferred Tax	1.2	0.4	0.7	1.2	0.7	2.3	-1.0	1.1	1.1	0.9	1.5	0.1
Tax Expense	2.9	3.1	3.9	5.3	5.8	6.1	7.9	6.9	7.6	4.4	10.0	5.9
+ Share of Associates & JVs	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-0.1	-0.0	0.0
Net Income	10.5	13.0	18.7	17.9	19.6	19.4	20.7	20.5	23.9	15.2	41.7	16.6
+ Net Income — Continuing Ops	10.5	13.0	18.7	17.9	19.6	19.4	20.7	20.5	23.9	15.3	41.7	16.5
+ Other Comprehensive Income	0.2	0.3	-0.7	-0.1	-0.1	-0.1	0.7	0.1	0.1	-0.1	0.1	0.1
Total Comprehensive Income	10.6	13.2	18.0	17.9	19.5	19.3	21.4	20.7	24.0	15.1	41.8	16.6
Net Income to Common	10.5	13.0	18.7	17.9	—	19.4	20.7	20.5	23.9	15.2	41.7	16.6
Per Share
Basic EPS	3.35	4.09	5.80	5.55	6.07	6.01	6.40	6.35	7.38	4.72	12.86	5.10
Diluted EPS	3.23	3.97	5.70	5.46	5.92	5.88	6.28	6.25	7.25	4.66	12.70	5.04
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	0.7	0.1	0.1	-0.1	0.1	0.1
+ Items NOT to be Reclassified to P&L	0.2	0.4	-0.9	-0.1	-0.1	-0.1	0.9	0.2	0.1	-0.1	0.1	0.1
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	0.2	0.0	0.0	-0.0	0.0	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.1	0.1	-0.2	-0.0	-0.0	-0.0	—	—	—	—	—	—
Comprehensive Income — Owners of Parent	10.6	13.2	18.0	17.9	—	19.3	21.4	20.7	24.0	15.2	41.8	16.6
Per Share — as-filed variants
Basic EPS — Continuing Operations	3.35	4.09	5.80	5.55	6.07	6.01	6.40	6.35	7.38	4.72	12.86	5.10
Diluted EPS — Continuing Operations	3.23	3.97	5.70	5.46	5.92	5.88	6.28	6.25	7.25	4.66	12.70	5.04
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	119.5	124.0	123.3	127.3	141.4	134.6	144.5	145.6	157.8	142.1	148.2	185.3
Gross Margin %	76.90	78.30	74.14	74.80	75.90	77.14	77.67	75.42	76.63	78.42	76.96	78.69
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	13.4	16.1	22.6	23.2	25.4	25.5	28.6	27.4	31.6	19.8	51.7	22.4
Net Income Adj (tax-effected)	10.5	13.0	18.7	17.9	19.6	19.4	20.7	20.5	23.9	15.2	41.7	16.6
EPS Adj	3.35	4.09	5.80	5.55	6.07	6.01	6.40	6.35	7.38	4.72	12.86	5.10
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00
Paid Up Equity Capital	15.7	16.1	16.1	16.1	16.1	16.1	16.1	16.2	16.2	16.2	16.2	16.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Krsnaa Diagnostics Q2 FY27 results date

Krsnaa Diagnostics (NSE: KRSNAA) will announce its Q2 FY27 results (July–September 2026) on Monday, 2 November 2026, according to the board-meeting notice it filed on 26 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹16.6 crore, down 19.3% from ₹20.5 crore in Q1 FY26 and down 60.3% from ₹41.7 crore in Q4 FY26. Revenue from operations was ₹236 crore, up 22.1% year on year and up 22.3% from the previous quarter.

Board-meeting notice filed: 26 October 2026
Q2 FY26 results (a year earlier): 7 November 2025
Q1 FY27 results (the latest): 13 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 2 November 2026Monday · notice filed 26 Oct
Q1 FY27 net profit: ₹16.6 Cr−19.3% vs Q1 FY26−60.3% vs Q4 FY26
Q1 FY27 revenue: ₹236 Cr+22.1% vs Q1 FY26+22.3% vs Q4 FY26
Q1 FY27 operating margin: 12.7%−2.7 pts vs Q1 FY26−4.0 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹23.9 CrRevenue ₹206 Cr
Q1 FY27 EPS (basic): ₹5.10

Questions

When will Krsnaa Diagnostics announce its Q2 FY27 results?

On 2 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 26 October 2026). Last year it reported Q2 FY26 on 7 November 2025.

What were Krsnaa Diagnostics' Q1 FY27 results?

Consolidated net profit was ₹16.6 crore, down 19.3% from ₹20.5 crore in Q1 FY26 and down 60.3% from ₹41.7 crore in Q4 FY26. Revenue from operations was ₹236 crore, up 22.1% year on year and up 22.3% from the previous quarter.

What was Krsnaa Diagnostics' net profit in FY26?

Consolidated net profit was ₹101 crore in FY26 (April 2025–March 2026), up 30.7% from ₹77.6 crore in FY25. It was ₹56.8 crore in FY24 and ₹62.1 crore in FY23: up 63.3% over three years, 17.8% a year on average.

What will Krsnaa Diagnostics' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹23.9 crore and revenue from operations ₹206 crore. The latest quarter, Q1 FY27, had a net profit of ₹16.6 crore and revenue of ₹236 crore.

How has Krsnaa Diagnostics' profit changed over the last four quarters?

Net profit by quarter: ₹23.9 crore in Q2 FY26, ₹15.2 crore in Q3 FY26, ₹41.7 crore in Q4 FY26 and ₹16.6 crore in Q1 FY27. That is ₹97.5 crore over the four quarters, up 21.5% from ₹80.2 crore in the four quarters before. Revenue from operations: ₹206 crore, ₹181 crore, ₹193 crore and ₹236 crore.

What was Krsnaa Diagnostics' revenue in FY26?

Revenue from operations was ₹773 crore in FY26 (April 2025–March 2026), up 7.8% from ₹717 crore in FY25. It was ₹620 crore in FY24 and ₹487 crore in FY23: up 58.6% over three years, 16.6% a year on average.

Where do these Krsnaa Diagnostics figures come from?

From Krsnaa Diagnostics' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.